Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Al Olama, AA
MetadataShow full item record
Germline mutations within DNA-repair genes are implicated in susceptibility to multiple forms of cancer. For prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 give rise to moderately elevated risk, whereas two of B100 common, low-penetrance PrCa susceptibility variants identified so far by genome-wide association studies implicate RAD51B and RAD23B.Genotype data from the iCOGS array were imputed to the 1000 genomes phase 3 reference panel for 21 780 PrCa cases and 21 727 controls from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. We subsequently performed single variant, gene and pathway-level analyses using 81 303 SNPs within 20 Kb of a panel of 179 DNA-repair genes.Single SNP analyses identified only the previously reported association with RAD51B. Gene-level analyses using the SKAT-C test from the SNP-set (Sequence) Kernel Association Test (SKAT) identified a significant association with PrCa for MSH5. Pathway-level analyses suggested a possible role for the translesion synthesis pathway in PrCa risk and Homologous recombination/Fanconi Anaemia pathway for PrCa aggressiveness, even though after adjustment for multiple testing these did not remain significant.MSH5 is a novel candidate gene warranting additional follow-up as a prospective PrCa-risk locus. MSH5 has previously been reported as a pleiotropic susceptibility locus for lung, colorectal and serous ovarian cancers.
UK Genetic Prostate Cancer Study Collaborators
UK ProtecT Study Collaborators
Genetic Predisposition to Disease
DNA Repair Enzymes
Cell Cycle Proteins
Polymorphism, Single Nucleotide
Genome-Wide Association Study
License start date
British journal of cancer, 2016, 114 (8), pp. 945 - 952
Showing items related by title, author, creator and subject.
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; Tan, M; Khan, A; Harris, V; McDonald, F; Lalondrelle, S; Mohammed, K; Thomas, K; Thompson, A; Kumar, P; Dearnaley, D; Horwich, A; Huddart, R (2016-04)Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare normal bladder ...
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Evans, JR; Zhao, SG; Chang, SL; Tomlins, SA; Erho, N; Sboner, A; Schiewer, MJ; Spratt, DE; Kothari, V; Klein, EA; Den, RB; Dicker, AP; Karnes, RJ; Yu, X; Nguyen, PL; Rubin, MA; de Bono, J; Knudsen, KE; Davicioni, E; Feng, FY (2016-04)A substantial number of patients diagnosed with high-risk prostate cancer are at risk for metastatic progression after primary treatment. Better biomarkers are needed to identify patients at the highest risk to guide therapy ...
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; Gao, A; Parker, CC; Huddart, R; Bidmead, M; Eeles, R; Khoo, V; van As, NJ; Hansen, VN; Dearnaley, DPPURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ...